Abstract: Disclosed are compounds and compositions that modulate cannabinoid receptors, methods of modulating cannabinoid receptors, and methods of treating various disorders related to the modulation of cannabinoid receptors. This disclosure is directed to methods of treating cannabinoid dependence, neuropathy, inflammation, glaucoma, a neurodegenerative disorder, a motor function disorder, a gastrointestinal disorder, hypothermia, emesis, loss of appetite, or anorexia associated with AIDS.
Type:
Grant
Filed:
December 11, 2020
Date of Patent:
April 23, 2024
Assignee:
Northeastern University
Inventors:
Alexandros Makriyannis, Spyridon P. Nikas, Ganeshsingh A. Thakur, Rishi Sharma, Shashank Kulkarni
Abstract: The present application relates to an anti-tumor compound and a preparation method and use thereof, and in particular to a compound or a tautomer, a mesomer, a racemate, an enantiomer or a diastereoisomer thereof, or a mixture thereof, or a pharmaceutically acceptable salt thereof, and a preparation method and use thereof.
Abstract: Many drugs useful in treating cancer are metabolized by CYP2C8 enzymes, by CYP3A4 enzymes, or both. The effects of concomitant administration of relacorilant and paclitaxel, a drug used to treat cancer that is a substrate for both CYP2C8 and CYP3A4, are disclosed herein. Relacorilant potently inhibited CYP2C8 and CYP3A4 in in vitro tests, indicating that co-administration of relacorilant and paclitaxel would increase paclitaxel plasma exposure more than 5-fold in vivo, requiring significant reductions in paclitaxel doses when co-administering paclitaxel with relacorilant. Surprisingly, paclitaxel plasma exposure increased only by about 80% instead of the expected more than 5-fold increase expected with concomitant relacorilant and paclitaxel administration. Applicant discloses safe methods of co-administering relacorilant and paclitaxel by reducing the dose of paclitaxel to about half the paclitaxel dose used when paclitaxel is administered alone.
Abstract: A seed germination activator for control of broomrape includes butylisobutylphthalate (hereinafter “BIP”). A biocontrol composition includes BIP and at least two nonionic surfactants for administration in irrigation water. Methods of controlling broomrape may include administering the biocontrol composition comprising BIP in the irrigation water prior to planting crops.
Type:
Grant
Filed:
August 17, 2023
Date of Patent:
April 2, 2024
Assignee:
KING FAISAL UNIVERSITY
Inventors:
Khaled Mohamed Amen Ramadan, Hossam El-Din Saad El-Beltagi, Hani Saber Sayed Saudy, Ahmed Zein El-Abdein Abdel Azeiz
Abstract: Provided are methods of sensitizing LKB1/STK11 deficient cancers to immune therapy. A method for treatment for LKB1/STK11 deficient cancers is provided comprising administration of inhibitor or inhibitors of one or more of NAMPT, CD38, SHP2, CXCR1/2, HDAC4 and PARP in combination with immunotherapy.
Abstract: The present invention relates to methods, compositions and kits for treatment of ribosomal disorders and ribosomopathies, e.g. Diamond Blackfan anemia (DBA). In some embodiments, the invention relates to the use of novel classes of compounds, i.e. inhibitors of RSK (p90S6K); inhibitors of p70S6K; and inhibitors of rps6, to treat ribosomal disorders and ribosomopathies. In some embodiments, the invention relates to the use of specific Chk2 inhibitors and to the use of specific phenothiazine derivatives to treat ribosomal disorders and ribosomopathies, e.g. DBA.
Type:
Grant
Filed:
February 12, 2021
Date of Patent:
April 2, 2024
Assignees:
THE CHILDREN'S MEDICAL CENTER CORPORATION, DANA-FARBER CANCER INSTITUTE, INC.
Inventors:
James Bradner, Jun Qi, Dennis Buckley, Leonard I. Zon, Elizabeth Macari
Abstract: A seed germination activator for control of broomrape includes butylisobutylphthalate (hereinafter “BIP”). A biocontrol composition includes BIP and at least two nonionic surfactants for administration in irrigation water. Methods of controlling broomrape may include administering the biocontrol composition comprising BIP in the irrigation water prior to planting crops.
Type:
Grant
Filed:
March 14, 2023
Date of Patent:
March 26, 2024
Assignee:
KING FAISAL UNIVERSITY
Inventors:
Khaled Mohamed Amen Ramadan, Hossam El-Din Saad El-Beltagi, Hani Saber Sayed Saudy, Ahmed Zein El-Abdein Abdel Azeiz
Abstract: Described is a method for the preparation of an oral levothyroxine composition, comprising the steps of combining levothyroxine or a salt thereof, a water-miscible organic solvent or a sugar alcohol and water, adjusting the pH to at least 8 providing a basic aqueous medium, dissolving the levothyroxine in the basic aqueous medium to yield a levothyroxine solution, and lowering the pH of the levothyroxine solution to between 3.5-4.9. also described is an oral levothyroxine composition obtainable by the said method and its use as a medicament.
Abstract: The present disclosure relates to a benzoselenophene-based compound, a method of preparing the benzoselenophene-based compound, and a pharmaceutical composition and antibody-drug conjugate including the benzoselenophene-based compound.
Type:
Grant
Filed:
July 29, 2022
Date of Patent:
March 26, 2024
Assignee:
AIMED BIO INC.
Inventors:
Dongyeol Lim, Min Cheol Kim, Amol Mhetre, Do-Hyun Nam
Abstract: The technology described herein relates to methods and compositions to prevent or treat vascular disease by targeting the epigenetic regulation of gene expression of vascular smooth muscle cell cytoskeletal proteins.
Type:
Grant
Filed:
February 19, 2019
Date of Patent:
March 26, 2024
Inventors:
Mark E. Lindsay, Christian Lacks Lino Cardenas, Rajeev Malhotra
Abstract: The disclosure is directed to compounds of Formula I pharmaceutical compositions comprising compounds of Formula I, as well as methods of their use and preparation, are also described.
Type:
Grant
Filed:
January 20, 2023
Date of Patent:
March 26, 2024
Assignee:
Prelude Therapeutics Incorporated
Inventors:
Jincong Zhuo, Xiaowei Wu, Katarina Rohlfing, Andrew Combs
Abstract: Methods of treating a seizure disorder with (1S,3S)-3-amino-4-(difluoromethylidene)cyclopentane-1-carboxylic acid, or (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid (KT-II-115), or a pharmaceutically acceptable salt of any of the preceding, are provided. The methods provide therapeutic compositions that may be used to improve one or more symptoms of a seizure disorder. Methods of treating Prader-Willi syndrome with (1S,3S)-3-amino-4-(difluoromethylidene)cyclopentane-1-carboxylic acid, or (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid (KT-II-115), or a pharmaceutically acceptable salt of any of the preceding, are provided. The methods provide therapeutic compositions that may be used to improve one or more symptoms of Prader-Willi syndrome.
Abstract: The present invention relates to N-acetylcysteine for the use in the treatment of bacterial infections caused by a pathogen selected from Burkholderia cepacia complex (BCC) and Stenotrophomonas maltophilia (S. maltophilia) strains.
Type:
Grant
Filed:
December 28, 2020
Date of Patent:
March 5, 2024
Assignee:
Zambon S.P.A.
Inventors:
Gian Maria Rossolini, Lucia Pallecchi, Francesco Sergio
Abstract: Provided herein are compositions and methods for the treatment of a cancer. Said compositions comprise a RAF inhibitor. Some embodiments comprise combination therapy featuring the RAF inhibitor with at least one oncology therapeutic agent.
Type:
Grant
Filed:
April 6, 2023
Date of Patent:
March 5, 2024
Assignee:
KINNATE BIOPHARMA INC.
Inventors:
Aleksandra Franovic, Eric Martin, Nichol L. G. Miller, Eric Murphy, Richard Thomas Williams, Ken Kobayashi
Abstract: A 3-(3-chlorophenyl)-5-((2-isopropyl-5-methylphenoxy)methyl)-1,2,4-oxadiazole compound, its synthesis, and its use as an antimicrobial agent.
Type:
Grant
Filed:
November 2, 2023
Date of Patent:
March 5, 2024
Assignee:
KING FAISAL UNIVERSITY
Inventors:
Hany Mohamed Abd El-Lateef Ahmed, Mai Mostafa Khalaf Ali, Antar Ahmed Abdelhamid Ahmed, Amer A. Amer
Abstract: The compound of formula (1a) wherein p is 1 or 2, R1-R4 are hydrogen atom or the like, and a-d are 1 or 2, or a pharmaceutically acceptable salt thereof, which has an antitumor effect by inhibiting the binding between a MLL fusion protein that is infused with AF4, AF9, or the like, which is a representative fusion partner gene causing MLL leukemia, and menin.
Abstract: A method of treating a cancer in a patient includes obtaining a sample from the patient, using a C-circle assay to detect a presence of an alternative lengthening of telomeres (ALT) phenotype in the sample, and administering an effect amount of at least one of PRIMA-1 or APR-246 to the patient.
Type:
Grant
Filed:
March 9, 2019
Date of Patent:
February 27, 2024
Assignee:
Texas Tech University System
Inventors:
Charles Patrick Reynolds, Balakrishna Koneru, Shawn Macha
Abstract: The present disclosure provides compounds and pharmaceutically acceptable salt thereof, and methods of using the same. The compounds and methods have a range of utilities as therapeutics, diagnostics, and research tools. In particular, the subject compositions and methods are useful for reducing signaling output of oncogenic proteins.
Type:
Grant
Filed:
June 2, 2023
Date of Patent:
February 27, 2024
Assignee:
KUMQUAT BIOSCIENCES INC.
Inventors:
Baogen Wu, Pingda Ren, Zhiyong Chen, Yi Liu
Abstract: The present invention relates to the field of cancer. More specifically, the present invention provides methods and compositions useful for the treatment of cancer characterized by TERT and BRAF mutations. In a specific embodiment, a method for treating a mutant telomerase reverse trancriptase (TERT) enzyme-associated cancer in a subject comprises the step of administering to the subject an anti-cancer agent that inhibits one or more of FOS, GABPB, the formation of the GABPA-GABPB complex or the binding of the GABPA-GABPB complex to a mutant TERT promoter.